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OBJECTIVES We compared the acute and one year medical costs and outcomes of coronary stenting with
those for balloon angioplasty (percutaneous transluminal coronary angioplasty) in contem-
porary clinical practice.
BACKGROUND While coronary stent implantation reduces the need for repeat revascularization, it has been
associated with significantly higher acute costs compared with coronary angioplasty.
METHODS We studied patients treated at Duke University between September 1995 and June 1996 who
received either coronary stent (n 5 384) or coronary angioplasty (n 5 159) and met eligibility
criteria. Detailed cost data were collected initially and up to one year following the procedure.
Our primary analyses compared six and 12 month cumulative costs for coronary angioplasty-
and stent-treated cohorts. We also compared treatment costs after excluding nontarget vessel
interventions; after limiting analysis to those without prior revascularization; and after
risk-adjusting cumulative cost estimates.
RESULTS Baseline clinical characteristics were generally similar between the two treatment groups. The
mean in-hospital cost for stent patients was $3,268 higher than for those receiving coronary
angioplasty ($14,802 vs. $11,534, p , 0.001). However, stent patients were less likely to be
rehospitalized (22% vs. 34%, p 5 0.002) or to undergo repeat revascularization (9% vs. 26%,
p 5 0.001) than coronary angioplasty patients within six months of the procedure. As such,
mean cumulative costs at 6 months ($19,598 vs. $19,820, p 5 0.18) and one year ($22,140
vs. $22,571, p 5 0.26) were similar for the two treatments. Adjusting for baseline predictors
of cost and selectively examining target vessel revascularization, or those without prior
coronary intervention yielded similar conclusions.
CONCLUSIONS In contemporary practice, coronary stenting provides equivalent or better one-year patient
outcomes without increasing cumulative health care costs. (J Am Coll Cardiol 1999;33:
1610–8) © 1999 by the American College of Cardiology
Efforts to reduce the rate of abrupt vessel closure and
restenosis associated with percutaneous balloon intervention
have led to the development and testing of coronary stents
(1–3). In randomized trials, elective stent use improved the
acute clinical success rate of the procedure and reduced the
rate of repeat revascularization compared with conventional
balloon angioplasty (percutaneous transluminal coronary
angioplasty) (4,5). However, stent implantation is costly
(6–8) and was initially thought to require aggressive post-
procedure oral anticoagulation (9). This adjuvant therapy
resulted in increased bleeding complications, longer in-
patient hospital stays and was associated with higher acute
care costs (10–12). While the reduced need for subsequent
revascularization procedures associated with stenting par-
tially offset their initial expense (13,14) at one year, costs for
patients receiving stents remained $800 to $4,600 higher
than for those receiving conventional coronary angioplasty
(13,15,16).
Since these initial studies, the use of coronary stents in
clinical practice has changed significantly. First, a post-stent
antiplatelet regimen including ticlopidine and aspirin has
been developed as an effective alternative to the use of oral
anticoagulation (17–19). This newer regimen is less likely to
cause bleeding complications and avoids the need for
extended hospitalizations. Second, the spectrum of patients
receiving stents has broadened considerably since the initial
randomized trials. While early studies included predomi-
nately low-risk patients (e.g., those with discrete, de novo
lesions in a single native vessel), current stent use includes
their implantation in more complex lesions, during mul-
tivessel interventions and in patients presenting with rest-
enotic lesions (2,3,20,21).
The purpose of this study was to compare the economic
and clinical outcomes of patients undergoing stenting with
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those receiving balloon angioplasty in a contemporary ter-
tiary care practice setting. Specifically, using an observa-
tional interventional database, we compared the initial and
follow-up clinical event rates and costs in patients receiving
a stent (and treated with ticlopidine/aspirin regimen) with
those for a clinically similar cohort of patients undergoing
conventional balloon angioplasty.
METHODS
Sample selection. All patients who underwent percutane-
ous coronary intervention at Duke University Medical
Center between September 1, 1995 and June 30, 1996 were
considered for the study. The baseline procedure was
defined as a patient’s first percutaneous revascularization
during this time period. Patients were excluded from this
cohort if at baseline:
1) the procedure involved laser, rotational or directional
atherectomy or TEC devices;
2) a non-Palmaz-Schatz coronary stent was implanted;
3) the left main or a saphenous vein graft was revascular-
ized;
4) acute myocardial infarction (MI) occurred within two
days preceding the procedure;
5) the revascularization was part of a staged series of
interventional procedures; or
6) an emergency bypass surgery immediately followed the
procedure.
Finally, because we wanted to compare outcomes in patients
who were candidates for either balloon angioplasty or stent
placement, patients with a target vessel diameter (as assessed
by the largest balloon size) of less than 2.7 mm in diameter
were excluded from the coronary angioplasty group.
Treatment protocol. Patients receiving coronary stents
were pretreated with aspirin (325 mg per day) and ticlopi-
dine (250 mg twice a day), ideally starting 24 h prior to the
procedure. Ticlopidine therapy was continued for up to four
weeks following stent implantation. Our standard labora-
tory practice is to use high pressure balloon inflation to
assure adequate stent strut expansion. Intravascular ultra-
sound (IVUS) was not routinely employed, and use of
abciximab was left to the operator’s discretion. In-lab
heparin use included a 10,000 unit bolus with additional
heparin as needed to maintain an activated clotting time
(ACT) .300 s (for those not receiving abciximab) and an
initial heparin bolus of 5,000 units and a target ACT of 200
to 250 s (for those receiving abciximab). Conventional
coronary angioplasty was performed using standard tech-
niques with a goal of achieving a residual stenosis diameter
of ,30%. Coronary angioplasty patients also received aspi-
rin, heparin and abciximab using regimens similar to those
described for stent patients. After the procedure all inter-
vention patients went to a monitored nonintensive care unit
(ICU) setting unless procedural complications required
more intensive monitoring. Our standard practice was to
discharge both stent and coronary angioplasty patients who
had no major complications on the day following the
procedure.
Data collection. Baseline clinical and demographic data
related to the index hospitalization were obtained from the
Duke Distributed Information System for Clinical Care and
a supplementary interventional catheterization laboratory
database. The databases include basic demographic data
(age, race, gender), comorbid illnesses, baseline clinical
characteristics, preprocedure and postprocedure laboratory
and diagnostic tests, in-lab procedure descriptors, proce-
dural complications and transfusion data (22).
Follow-up resource use and health status was assessed
through telephone interviews conducted at 6 and 12 months
following the procedure. The telephone interview deter-
mined the dates and locations of any hospitalizations,
outpatient catheterizations, the occurrence of major clinical
events (MI, death, revascularization), the severity of angina
(Canadian Cardiovascular Society [CCS] angina class) and
work status. Patient-reported clinical events and resource
use during follow-up were confirmed by obtaining the
hospital discharge summaries and hospital billing informa-
tion. In addition, we used the Duke clinical databases to
identify any unreported Duke hospitalizations or out-
patient procedures. This study protocol was reviewed and
approved by the internal review board of our institution.
Follow-up hospital admissions were classified as being for
cardiac or noncardiac indications by the study investigators
who were blinded to treatment status. Cardiac hospitaliza-
tions included those for any type of chest pain, revascular-
ization procedure, congestive heart failure, arrhythmia and
other miscellaneous cardiovascular diagnoses. Hospitaliza-
tions for clearly unrelated illnesses (e.g., fractures, cancer)
were considered to be noncardiac, unless the event was
determined to be a possible direct complication of a cardiac
procedure (e.g., readmission for pseudoaneurysm repair).
Cost calculation methodology. Baseline cost data were
extracted from the Duke Transition 1 Accounting System
(Transition Systems, Inc., Boston, Massachusetts). This
system contains detailed cost records at the intermediate
product level within each department. Specifically, the cost
of an admission was calculated by multiplying the quantity
of each resource used (e.g., hours of care by inpatient unit,
hours in the catheterization lab, number of diagnostic tests
Abbreviations and Acronyms
ACT 5 activated clotting time
CCS 5 Canadian Cardiovascular Society
COPD 5 chronic obstructive pulmonary disease
ICU 5 intensive care unit
IVUS 5 intravascular ultrasound
LAD 5 left anterior descending artery
MI 5 myocardial infarction
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by type of test, among others) by the unit cost of the
resource, and then totalling the resultant individual resource
costs.
Follow-up resource use was limited to cardiac hospital-
izations and outpatient catheterizations. The cost of subse-
quent cardiac care at Duke was also calculated using the
Transition 1 accounting system. Subsequent cardiac care
cost at hospitals other than Duke was estimated from
hospital charge data using standard department-level cost-
to-charge methodology (23). Physician fees were based on
the 1996 North Carolina Medicare Physician Fee Schedule.
Professional fees were assigned for major cardiac procedures
(inpatient and outpatient catheterization, percutaneous in-
tervention, bypass surgery) and daily inpatient care on
routine and critical care units. Finally, all costs were stan-
dardized to 1996 dollars.
Statistical analyses. Because physicians do not routinely
record prior to the procedure whether a stent or balloon
angioplasty procedure was planned, an intention-to-treat
analysis was not possible in this study. Instead, we classified
patients based on whether they received a coronary stent
during their procedure. Procedures classified as stent cases
may include those where initial balloon angioplasty was
attempted but suboptimal results (i.e., coronary dissection)
necessitated coronary stent placement. Balloon angioplasty
cases may include those in which stent placement was
planned but was not technically feasible and those in which
the initial balloon dilation resulted in such good angio-
graphic outcomes that stent placement was deferred.
Our primary cost analyses compared baseline, six and 12
month cumulative costs for the coronary angioplasty and
stent cohorts. Secondary outcomes included six-month and
one-year clinical event rates: death, myocardial infarction,
rehospitalization rates, need for repeat revascularization
procedures, CCS angina class and work status. Clinical risk
factors, costs and clinical events were compared using
chi-square or Wilcoxon tests as appropriate. Baseline hos-
pitalization costs were examined at the department level.
Cumulative costs were compared using Student t tests after
log transformation.
In addition to comparing the cost and outcomes for all
cardiac rehospitalizations, we also conducted several sec-
ondary analyses to assess the robustness of the results. First,
we excluded follow-up revascularizations in vessels other
than the baseline target vessel. Second, we repeated the
analyses after excluding patients with prior coronary revas-
cularization procedures. This patient subsample is more
consistent with the inclusion criteria from prior randomized
clinical trials (4,5). Finally, because this study was observa-
tional and treatment selection factors could lead to baseline
differences in risk factors between treatment groups, we
adjusted our baseline and cumulative cost comparisons for
potential confounding clinical risk factors.
Our risk-adjustment strategy involved four steps. First,
baseline costs were risk adjusted using multiple regression
analysis after log transformation. Variables considered as
candidates in the model included the following: demo-
graphics (age, race, gender), comorbid illness (chronic
pulmonary obstructive disease (COPD), congestive heart
failure, diabetes mellitus), disease severity (prior MI, prior
revascularization procedure, multivessel disease and baseline
CCS angina class), a proxy for the size of the intervened
coronary vessel (largest dilator balloon size used) and initial
treatment strategy (stent vs. coronary angioplasty). Second,
the probability of readmission was modeled using logistic
regression, adjusting for similar explanatory variables.
Third, the cost of hospitalization given readmission was
modeled using multiple regression (after log transforma-
tion). Finally, Monte Carlo analysis was used to estimate
the risk-adjusted cumulative costs at one year, based on the
risk-adjusted estimates of baseline cost, probability of read-
mission and cost of readmission (24).
RESULTS
Patient sample. Of the 1,039 unique patients at Duke
University Medical Center who underwent conventional
balloon angioplasty or received a Palmaz-Schatz coronary
stent between September 1, 1995 and June 30, 1996, 530
received coronary angioplasty and 509 received at least
one coronary stent. We excluded 258 coronary angio-
plasty patients (51%) in whom the largest balloon used
for dilation was less than 2.7 mm. Of the remaining
patients in both groups, we excluded 92 patients (12%)
who received intervention for left main or saphenous vein
graft disease, 111 patients (14%) whose procedure oc-
curred within two days of an acute myocardial infarction,
14 patients (2%) with staged revascularization procedures, 18
patients (3%) with missing baseline or follow-up data and 4
patients (,1%) who required emergent bypass surgery (1 stent
patient and 3 coronary angioplasty patients). Thus, our final
data set included 384 stent and 159 coronary angioplasty
patients.
Baseline characteristics. Demographic characteristics of
patients were generally similar in the stent and coronary
angioplasty groups (Table 1). The mean age was 60 and 62
years, respectively, in the stent and coronary angioplasty
groups. More than half of both groups were white men.
Prior myocardial infarction, CCS angina class and comorbid
illnesses were also similar in the two treatment groups. Stent
patients were less likely to have undergone prior bypass
surgery (9% vs. 17%, p 5 0.01) or coronary angioplasty
(17% vs. 23%, p 5 0.09) than percutaneous transluminal
coronary angioplasty patients. The target lesion was more
often in the left anterior descending (LAD) coronary artery
in stent patients than in coronary angioplasty patients (33%
vs. 21%, p 5 0.006). Finally, multivessel coronary interven-
tion was attempted in 9% of stent cases and 6% of coronary
angioplasty cases.
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Resource use during index hospitalization. The total
length of stay for stent and coronary angioplasty patients
was similar, averaging 3.6 and 3.8 days, respectively (Table
2). The length of stay after the procedure was also similar in
the two groups. Despite similar lengths of stay, the mean
total cost of hospital care was over $3,200 higher in the stent
group than in the coronary angioplasty group ($14,802 vs.
$11,534, p , 0.001). The cost differential in the stent group
was due almost entirely to higher catheterization lab costs
($9,780 vs. $6,224, p , 0.001) with all other departmental
costs being similar (Table 2). The higher catheterization lab
costs arose primarily from the cost of stents and to some
extent to slightly increased use of coronary angioplasty
balloons (Table 3). In contrast, abciximab was used in
slightly fewer stent than coronary angioplasty cases (28% vs.
35%, p 5 0.15).
Follow-up events. During the six months following their
baseline procedure, stent patients were significantly less
likely to be readmitted for cardiac care than coronary
angioplasty patients (22% vs. 34%, p 5 0.002) (Table 4).
Cardiac catheterization was performed half as often in
stent patients (17% vs. 35%, p 5 0.001). Coronary
revascularization procedures were also used significantly
less often in stent patients than in patients undergoing
coronary angioplasty with 7% versus 20% (p 5 0.001)
receiving a repeat percutaneous coronary intervention
within six months and 3% versus 8% (p 5 0.01) requiring
bypass surgery. Of note, 73% of coronary angioplasty
patients who required a repeat percutaneous coronary
intervention within six months received a stent as a part
of their follow-up procedure, thereby confirming their
baseline eligibility for stent implantation.
Table 1. Baseline Characteristics for Stent and PTCA Patients
Stent
(n 5 384)
PTCA
(n 5 159)
p
Value
Mean Age (yr) 60 62 0.09
Gender (% male) 67 73 0.21
Race (% white) 84 83 0.87
History of (%)
Myocardial infarction 54 59 0.30
Chronic pulmonary disease 12 9 0.49
Congestive heart failure 9 13 0.24
Diabetes mellitus 22 27 0.17
Prior Procedures (%)
Bypass surgery 9 17 0.01
PTCA only 17 23 0.09
# Diseased Vessels (%) 0.58
One 72 71
Two 21 15
Three 7 14
CCS Angina Class (%) 0.07
No angina 22 28
Class I or II 13 16
Class III or IV 65 56
Location of Intervention (%) 0.006
RCA 42 47
LAD 33 21
LCX 16 26
Multivessel Intervention (%) 9 6
Table 2. Baseline Hospitalization Resource Use
Stent
(n 5 384)
PTCA
(n 5 159)
p
Value
Length of Stay (days) 0.80
Mean 3.6 3.8
Median 3.0 3.0
Post Procedure LOS1 (days) 0.62
Mean 2.2 2.3
Median 1.0 2.0
Mean Department Cost ($)
Catheterization
laboratory
9,780 6,224 , 0.001
Room-intensive care unit 1,368 1,402 0.79
Room-routine care 1,309 1,419 0.88
Emergency room 787 756 0.35
Laboratory tests 385 345 0.01
Pharmacy 302 289 0.89
Other 871 1,100 0.90
In-Hospital Costs ($) , 0.001
Mean 14,802 11,534
Median 12,766 9,165
Professional Fee ($) , 0.001
Mean 1,863 1,816
Median 1,740 1,657
Total In-Hospital Costs ($) , 0.001
Mean 16,665 13,350
Median 14,629 10,764
LOS 5 length of stay.
Table 3. Baseline Catheterization Resource Use
Stent
(n 5 384)
PTCA
(n 5 159)
p
Value
Balloons
Mean number 2.1 1.8
Mean cost ($) 1,759 1,479 , 0.001
Stents*
Mean number 1.5 0.07
Mean cost ($) 3,629 169 , 0.001
Abciximab
% Patients 28 35
Mean cost ($) 661 817 0.15
Guide Caths/Wire
Mean cost ($) 481 490 0.64
Contrast Dye
Mean cost ($) 556 504 0.04
Other
Mean costs ($) 2,694 2,765 0.82
Total ($) , 0.001
Mean cost 9,780 6,224
Median cost 8,971 5,763
*Stents in the PTCA group include stents placed in repeat procedures during the
baseline hospitalization.
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Resource use after the initial six month follow-up period
was low in both treatment groups. By one year 29% of stent
patients had at least one readmission compared with 42% of
coronary angioplasty patients (p 5 0.006). Similarly, stent
patients were half as likely as coronary angioplasty patients
to receive a repeat revascularization procedure by one year
(14% vs. 30%, p 5 0.001).
In terms of patient clinical outcomes, death during
follow-up was uncommon (3%) in both groups. Stent
patients were slightly less likely to have a myocardial
infarction in the one-year follow-up period (2% vs. 5%, p 5
0.04). In addition, stent patients reported slightly less
angina at six months (27% vs. 36%, p 5 0.07) and at one
year (23% vs. 29%, p 5 0.14). If employed at baseline, stent
patients were also more likely than coronary angioplasty
patients to remain employed six months (86% vs. 66%, p 5
0.001) and one year (75% vs. 63%, p 5 0.06) following the
procedure.
Follow-up costs. The initial expense associated with stent
placement ($3,268) was completely offset by higher costs for
the coronary angioplasty-treated patients during the first six
months of follow-up (Fig. 1). Thus, cumulative mean costs
were equivalent in stent and coronary angioplasty groups at
six months ($19,598 vs. $19,820, respectively; p 5 0.18).
Costs during months 7 through 12 were low in both groups
(Table 5), resulting in similar one-year cumulative costs for
the two therapies ($22,140 for stent, $22,571 for coronary
angioplasty, p 5 0.26).
We repeated this cumulative cost analysis after excluding
the costs associated with nontarget vessel interventions.
This analysis eliminated approximately 12% of all repeat
interventions. While removal of nontarget revascularization
reduced costs slightly for both intervention groups, the
cumulative one-year costs for the two treatment strategies
remained similar ($21,966 for stent and $21,795 for coro-
nary angioplasty, p 5 0.14).
We also repeated the cost analyses after excluding all
patients who had been revascularized prior to the baseline
intervention. In this de novo intervention subgroup, stent
patients (n 5 285) continued to have lower rates of
rehospitalization (29% vs. 40%, p 5 0.04), cardiac cathe-
terization (26% vs. 39%, p 5 0.02) and revascularization
procedures (14% vs. 31%, p 5 0.001) than coronary angio-
plasty patients (n 5 95) during one-year follow-up. Addi-
tionally, one-year cumulative health care costs for de novo
stent patients remained similar to those for de novo coro-
nary angioplasty patients ($22,255 vs. $21,810, p 5 0.32).
Risk-adjusted cumulative one-year costs. Risk-adjusted
costs were based on three components: baseline costs, the
probability of rehospitalization and the cost of any
follow-up hospitalizations. The impact of risk factors on
each of the components was examined using regression
analysis. Baseline in-patient hospital costs increased with
increasing patient age, congestive heart failure, COPD and
Figure 1. Displays mean baseline in-hospital costs for Stent (light
bar) and PTCA (dark bar). It also displays mean 1–6 month and
7–12 month follow-up cardiac costs and cumulative six-month and
one-year cardiac costs for each treatment.
Table 4. Follow-up Resource Use and Clinical Outcomes
6-Month Event Rates 1-Year Event Rates
Stent
(n 5 384)
PTCA
(n 5 159)
p
Value
Stent
(n 5 384)
PTCA
(n 5 159)
p
Value
Readmissions (%)* 22 34 0.002 29 42 0.006
One 15 21 17 23
Multiple 7 13 12 19
Cardiac Catheterization (%) 17 35 0.001 27 43 0.001
Any Repeat Revascularization (%) 9 26 0.001 14 30 0.001
Percutaneous intervention 7 20 0.001 11 24 0.001
Coronary bypass surgery 3 8 0.01 6 11 0.03
Death (%) 3 2 0.6 3 3 0.7
Myocardial Infarction (%) 1 4 0.013 2 5 0.04
Any Angina (%) 27 36 0.07 23 29 0.14
CCS Class 1 or 2 20 28 17 19
CCS Class $3 7 8 6 10
Work Status* (% employed) 86 66 0.001 75 63 0.06
*Percentage of those employed at baseline who were working at follow-up.
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prior MI. After risk adjustment, treatment group (coronary
angioplasty) remained the strongest independent predictor
of baseline cost.
The probability of rehospitalization within six months
was less affected by baseline risk factors with only
diabetes mellitus (p 5 0.003) and COPD (p 5 0.11)
appearing related. Initial treatment with coronary angio-
plasty was, however, strongly associated with increased
rates of rehospitalization. The cost of rehospitalization
during the first six months was inversely related to the
maximum balloon size used for dilation (a proxy for vessel
size) and by initial treatment. Patients with smaller
coronary vessels and those undergoing coronary angio-
plasty had significantly higher costs for rehospitalization
(owing to the higher rates of repeat revascularization
during these rehospitalizations). During the second six
month follow-up period, event rates were low in both
groups and the probability of rehospitalization was un-
related to baseline risk factors or treatment group. Sim-
ilarly, the cost of rehospitalization was only weakly
associated with a baseline history of COPD.
To calculate cumulative risk-adjusted costs for stent and
coronary angioplasty patients, we used a Monte Carlo
analysis which incorporated regression-based cost and prob-
ability estimates. Figure 2 shows the cumulative risk-
adjusted mean cost (with 25th and 75th percentile confi-
dence limits) for a 60-year old male patient with a single
vessel baseline intervention (using a 3.0 mm balloon) with
three alternative risk profiles: no comorbid illness, with
diabetes mellitus and with multiple comorbid conditions.
For patients without comorbid illness, stent and coronary
angioplasty patients had similar one-year mean cumulative
health care costs ($20,336 vs. $20,320). As expected, cumu-
lative health care cost estimates rose with increasing comor-
bidity in both treatment groups. However, as those with
increasing baseline risk were more likely to require repeat
intervention, the relative effect of initial treatment strategy
on cumulative costs increased. For example, among those
with diabetes, patients receiving stents had $1,400 lower
estimated one-year mean costs than those receiving coro-
nary angioplasty ($21,300 vs. $22,700).
DISCUSSION
This study compared one-year clinical outcomes and cumu-
lative resource use for patients receiving a coronary stent and
adjuvant ticlopidine/aspirin therapy with those patients
receiving balloon angioplasty only. Our results suggest that
the acute expense associated with stent implantation can be
largely offset within six months by reductions in the need for
repeat interventions. Thus, in contemporary practice, coro-
nary stenting appears to lead to improved patient outcomes
without increasing long-term resource requirements when
compared with conventional balloon angioplasty.
Our study represents one of the first long-term economic
analyses comparing stenting with ticlopidine/aspirin therapy
to conventional coronary angioplasty. Consistent with other
case series, we found that in-hospital costs associated with
stenting had declined by approximately 20% after the
Figure 2. Displays risk-adjusted one year cumulative cost esti-
mates for patients receiving either a coronary stent or PTCA under
three clinical scenarios: 1) a 60-year old patient without comorbid
illness, 2) the same aged patient with diabetes mellitus, and 3) the
same aged patient with multiple comorbid illnesses (diabetes,
chronic lung disease, congestive heart failure, history of myocardial
infarction and multivessel coronary disease). The solid squares
mark the mean for each treatment under each scenario. The
diamond and triangles represent the 75th and 25th percentile
confidence intervals surrounding this mean estimate.
Table 5. Summary of Baseline and Follow-up Costs*
Stent
(n 5 384)
PTCA
(n 5 159)
p
ValueMean Mean
Baseline
Hospital cost 14,802 11,534
Inpatient professional fees 1,861 1,732
Total 16,663 13,266 , 0.001
1–6 Month Follow-up
Hospital costs 2,451 5,431
Inpatient professional fees 339 789
Outpatient catheterization† 144 333
Total 2,935 6,554 , 0.001
Cumulative 6-Month Costs
Hospital cost 17,254 16,965
Inpatient professional fees 2,201 2,521
Outpatient catheterization† 144 333
Total 19,598 19,820 0.18
7–12 Month Follow-up
Hospital cost 2,025 2,213
Inpatient professional fees 285 309
Outpatient catheterization† 231 229
Total 2,542 2,751 0.11
Cumulative 1-Year Costs
Hospital cost (all
patients)
19,279 19,178
Inpatient professional fees 2,486 2,831
Outpatient catheterization† 375 561
Total 22,140 22,571 0.26
*All costs expressed in 1996 dollars. †Includes professional fees.
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initiation of ticlopidine/aspirin in place of oral anticoagula-
tion (25,26). These cost reductions were due primarily to
reductions in lengths of stay following the procedure. While
the acute cost of coronary stenting has declined, we found
that stenting remains $3,200 more expensive than coronary
angioplasty, due almost entirely to the cost of the 1.5 stents
placed on average per case (Table 3).
In contrast to previous randomized trials (15,27,28), we
found that the acute added costs of stents were largely, if not
entirely, offset by lower rehospitalization costs within six
months of the procedure (Tables 4 and 5). Several factors
may account for the different findings. First, our patient
population had higher baseline risk than patients enrolled in
the randomized trials (Table 6). In particular, both stent and
coronary angioplasty patients had higher rates of diabetes
mellitus, more frequent prior coronary intervention and
required more multivessel baseline interventions than those
enrolled in randomized trials. One would expect that, if the
relative benefits of stent implantation are constant across
patient types, the absolute benefits of stenting (in terms of
reducing follow-up revascularization procedures) will be
greatest in those patients with the highest baseline risk for
restenosis.
Second, while we attempted to minimize treatment
selection bias by applying stringent inclusion criteria, we
may not have completely eliminated this bias in our obser-
vational analysis. To address this, we investigated the
robustness of our findings by restricting our analysis to
target vessel interventions and second, to a sample of
patients without a history of revascularization. In both of
these subsets, our overall results were unchanged. Further-
more, we risk-adjusted cumulative costs for baseline clinical
predictors of cost. Again, the risk-adjusted analyses dem-
onstrated that stent-treated patients had similar or lower
cumulative one-year treatment costs compared with those
receiving coronary angioplasty.
Comparison of the relative effectiveness of stents found in
our study versus those from prior randomized trials serves as
a final check for selection biases. Our study found that stents
were associated with a 53% reduction in the need for repeat
revascularization. This relative effectiveness for stenting was
higher than that noted in the STRESS and Benestent I
study (15,27) but was quite similar to that reported in the
preliminary results from the clinical follow-up arm of the
Benestent II trial, a contemporary stent study (28,29).
Indeed, others have reported that stent restenosis rates are
declining over time with more experience and improved
deployment techniques (30,31).
A third difference between our study and prior ran-
domized trials concerns treatment classification. In con-
trast to prior randomized trials (which used an intention
to treat analysis and had up to 20% initial treatment
crossover rates), our study classified all patients by the
initial treatment they received. As a result, initial proce-
dure cost estimates in our coronary angioplasty cohort
were lower (without crossover stent costs), but follow-up
intervention rates may have been increased in this treat-
ment group (as none initially received a stent). Alterna-
tively, by including patients who required stent place-
ment for initial suboptimal angioplasty results (24%) or
bail-out (3%) indications, our initial and follow-up cost
estimates in our stent cohort may actually have been
inflated as these complicated patients may have had worse
outcomes. Finally, our coronary angioplasty cohort in-
cluded patients in whom stent placement was not tech-
nically possible (e.g., ostial or bifurcation lesions) and
Table 6. Baseline Characteristics and 1-Year Event Rate Comparison With Prior
Randomized Studies
Duke
(n 5 543)
STRESS*
(n 5 207)
Benestent†
(n 5 516)
Benestent II‡
(n 5 405)
Baseline Characteristics (%)
Mean age (yr) 60 61 57 59
Gender (% male) 69 72 81 78
History of (%)
Myocardial infarction 55 35 19 26
Diabetes mellitus 23 15 n/a 12
Prior procedures (%)
Bypass surgery 11 1 1 2
PTCA 24 3 2 7
One Year Outcomes (%)
Any revascularization
(Stent vs. PTCA)
14 vs. 30 15 vs. 21 26 vs. 33 8 vs. 17
Percutaneous intervention
(Stent vs. PTCA)
11 vs. 24 13 vs. 18 18 vs. 27 8 vs. 17
Coronary bypass surgery
(Stent vs. PTCA)
6 vs. 11 6 vs. 11 8 vs. 6 1 vs. 1
*Source: STRESS Economic Substudy population (15). †Source: Benestent one year analysis (27). ‡Source: Preliminary results
from Benestent II Economic Substudy (16,29).
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who may be more prone to restenosis. While we did not
have detailed angiographic characteristics to address this
issue, the fact that three-quarters of patients initially
undergoing only coronary angioplasty received a stent in
a follow-up intervention suggests that this bias was
minimal.
Clinical and economic implications. Our study has sev-
eral clinical and economic implications. First, it is reassuring
to note that the clinical benefits of coronary stenting (in
terms of decreasing repeat interventions) found in early
randomized trials appear to be mirrored in our current
observational cohort. While our study was a nonrandomized
comparison, our study population more likely reflects
present day clinical practice (with higher baseline patient
risk factors and more complex interventional procedures).
Thus, the results support the generalization of the findings
from more selective populations in randomized trials.
Our study also investigated the impact of stenting on a
patient’s angina and work status (Table 5). We found that
stent patients were slightly more likely to be angina-free at
six months and one year than those initially receiving
coronary angioplasty (73% vs. 64%, p 5 0.07) and (77% vs.
71%, p 5 0.14), respectively. This impact of stents on
anginal status is similar to that seen in prior randomized
studies (5). For those initially employed, 86% of stent
patients were employed at six months versus 66% for
coronary angioplasty patients (p 5 0.001). At one year,
these comparison employment rates were 75% versus 63%
(p 5 0.06), respectively.
From an economic standpoint, we found that the acute
hospital costs of stent implantation in the era of ticlopidine/
aspirin remained considerably higher than conventional
coronary angioplasty, but both therapies had similar long-
term cumulative costs. In a prospective fee-for-service
environment, stent implantation can presents a “lose-lose
situation” from a hospital’s cost perspective. Stent use drives
up procedural costs while lowering downstream revenue
from repeat procedures. From a societal economic view-
point, however, stents appear to be becoming an almost
dominant strategy relative to coronary angioplasty, provid-
ing better long-term patient outcomes (fewer symptoms and
repeat hospitalizations) at similar expense.
STUDY LIMITATIONS
Several limitations of this study must be considered. First,
and most importantly, our study was observational and
comparability of the two study treatment cohorts cannot be
definitively established. Second, our study reflects findings
from a single high-volume university hospital and outcomes
in other settings may be significantly different. Third,
interventional technology is changing rapidly and these
results do not reflect the potential impact of newer coronary
stent designs (32) or more wide-spread use of glycoprotein
IIb/IIIa receptor inhibitors (33–35). Fourth, our follow-up
study did not include costs for cardiac medications or office
visits. As patients receiving stents had fewer downstream
symptoms, our current estimates may have underestimated
the economic benefits of stenting relative to coronary
angioplasty. We also did not include indirect costs associ-
ated with loss of employment. Again, as stent patients
working at baseline were more likely to remain employed
during follow-up procedures, stent implantation may actu-
ally be cost-saving if direct and indirect costs are considered.
CONCLUSIONS
In conclusion, our study of contemporary stent and coronary
angioplasty strategies appears to demonstrate that stents
improve patient outcomes at little, if any, additional long-
term cost. As stent prices are likely to decline with increased
competition from newly approved stents, the economic
attractiveness of this technology seems assured.
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